Biologics Naming: WHO Final Plan, FDA Draft Guidance Incompatible

US regulator could try to harmonize its nonproprietary naming approach with World Health Organization's biological qualifier system or stick with its suffix-based proposal; while having different names across the globe for a single product is not ideal, it's also not an insurmountable problem, experts say.

More from Drug Safety

More from Pink Sheet